Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Entheon Biomedical Corp C.ENBI

Alternate Symbol(s):  ENTBF

Entheon Biomedical Corp. is a Canada-based biotechnology research and development company. The Company is focused on treating addiction and substance-use disorders.


CSE:ENBI - Post by User

Entheon Biomedical Corp
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1921)
•••
Post by Betteryear2on Feb 27, 2022 3:58pm
241 Views
Post# 34465997

Entheon Biomedical Announces EBIQ-101 First-Patient Dose

Entheon Biomedical Announces EBIQ-101 First-Patient DoseVancouver, British Columbia--(Newsfile Corp. - February 24, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, is pleased to provide an update on its Observational Study, EBIQ-101.

Entheon Biomedical Announces EBIQ-101 First-Patient Dose
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities